## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%); PEG 4.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($665.92)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. 1,735 Shares in IDEXX Laboratories, Inc. $IDXX Bought by Stance Capital LLC**
- Source: MarketBeat | 20251215T115828 | Bullish | Relevance: 100%
- Stance Capital LLC recently acquired 1,735 shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock, valued at approximately $931,000, as disclosed in their latest SEC filing. This acquisition is part of a broader trend of institutional investors adjusting their positions in IDEXX, with the stock currently trading down 0.5%. The company reported strong financial results in its last earnings call, beating analyst estimates, and has received a "Moderate Buy" consensus rating from analysts, with an average target price of $763.50.

**2. With EPS Growth And More, IDEXX Laboratories (NASDAQ:IDXX) Makes An Interesting Case**
- Source: 富途牛牛 | 20251214T200820 | Bullish | Relevance: 100%
- IDEXX Laboratories (NASDAQ:IDXX) presents an interesting investment case due to its consistent EPS growth of 17% annually over three years and 8.4% revenue growth to US$4.2 billion. Insiders also hold a significant stake worth US$552 million, representing 1.0% of the company, which aligns their interests with shareholders. This combination of strong financial performance and insider confidence suggests IDEXX Laboratories warrants further investigation by investors.

**3. Frontier Capital Management Co. LLC Sells 6,851 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251212T130827 | Somewhat-Bullish | Relevance: 100%
- Frontier Capital Management Co. LLC has reduced its stake in IDEXX Laboratories, Inc. by selling 6,851 shares, now owning 109,065 shares valued at approximately $58.50 million. This comes as IDEXX Laboratories reported strong Q2 earnings, surpassing expectations with $3.22 EPS and $1.11 billion in revenue, and has a "Moderate Buy" consensus rating from analysts. Additionally, an IDEXX EVP also sold a significant number of shares, reducing her holdings by over 30%.

**4. Marshall Wace LLP Trims Holdings in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251212T110846 | Somewhat-Bullish | Relevance: 100%
- Marshall Wace LLP significantly reduced its stake in IDEXX Laboratories by 81.9% in Q2, selling 90,549 shares, leaving 20,000 shares valued at $10.73 million. Concurrently, IDEXX's EVP Nimrata Hunt sold 9,425 shares, decreasing her ownership by 30.83%. Despite these sales, IDEXX beat quarterly estimates and holds a "Moderate Buy" consensus rating with an average price target of $763.50.

**5. IDEXX Laboratories, Inc. $IDXX Position Trimmed by State Street Corp**
- Source: MarketBeat | 20251212T110845 | Bullish | Relevance: 100%
- State Street Corp reduced its stake in IDEXX Laboratories by 2.6% in the second quarter, selling 95,454 shares, though it still holds over 3.5 million shares valued at approximately $1.91 billion. Despite State Street's trim, other major institutional investors like Price T. Rowe and Bank of New York Mellon significantly increased their positions, pushing total institutional ownership to 87.84%. IDEXX (NASDAQ:IDXX) reported strong Q3 earnings, beating EPS and revenue estimates, and analysts maintain a "Moderate Buy" rating with an average target price of $763.50.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.16 signals overvaluation risk, limited margin of safety. Forward P/E 48.8x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.3B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.16 |
| Forward P/E | 48.8 |
| Current P/E | 54.6 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.8% to -0.1% (+4.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). MRS_5 turning positive (1.4%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.25x) but short-term weakness (below SMA20). MACD histogram bearish (-5.83), momentum weakening. RSI neutral at 49. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.15% (CS: 26) | Neutral |
| RSI_14 | 49.3 | Neutral |
| MACD Histogram | -5.83 | Bearish |
| vs SMA20 | 0.984x | Below |
| vs SMA50 | 1.034x | Above |
| vs SMA200 | 1.245x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $704.20
- **Stop Loss:** $665.92 (5.4% risk)
- **Target:** $742.48 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 26
- **Position Value:** $18,309.20
- **Portfolio %:** 18.31%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*